Method for treating vaso occlusive crises associated with Sickle cell disease
AssigneesNicox S.A., Fera Pharmaceuticals, LLC
InventorsBrigitte Duquesroix-Chakroun, Frank J. Dellafera, Scott Florentino
Life of this patent
Estimating the term…
Abstract
The present invention relates to a treatment of vaso-occlusive crisis (VOC) associated with Sickle cell disease by administering a therapeutically effective amount of 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate.
Claims8
A method for treating a vaso-occlusive crisis comprising administering a therapeutically effective amount of 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate to a Sickle cell anemia patient, wherein the 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate is administered in a dosage from 100 mg/day to 3000 mg/day.
A method for treating a vaso-occlusive crisis comprising administering a therapeutically effective amount of 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate to a Sickle cell anemia patient, wherein the 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate is administered in a dosage of from 15 to 22.5 mg per kg per day.
Dependencies are inferred from the claim text.